DadFinStart your free week
DadFin › Stocks › Healthcare › ALVO

Alvotech (ALVO) stock score

Healthcare · Drug Manufacturers - Specialty & Generic · Luxembourg

$5.78 ▲ +1.94% today

64.0
Dad Score, out of 100
middling

Alvotech (ALVO) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, listed in Luxembourg. On DadFin's weekly run it scores 64.0 out of 100 on the Dad Score, a middling reading that places the business ahead of 64% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #309 of 974. Its strongest axes are quality, price action and macro; its weakest are risk and liquidity.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Average
Quality
Above average
Growth
Average
Price action
Above average
Risk
Weak
Conviction
Average
Liquidity
Below average
Macro
Above average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)0.0×
P/E (forward)23.9×
Dividend yield0.00%
Return on capital23.1%
Operating margin-11.1%
Revenue growth (YoY)+19.7%
FCF yield-4.8%
Net debt / EBITDA17.28×
Piotroski F-Score2 / 9
52-week change-36.5%
Market cap$1.9B
Next earningsNov 11, 2026

What subscribers see on ALVO

Start your free weekSubscriber? Open the full research →

Drug Manufacturers - Specialty & Generic peers

StockCompanyDad ScoreBandMarket cap
TAKTakeda Pharmaceutical Company Limi32.9weak$57.1B
TEVATeva Pharmaceutical Industries Lim93.6strong$46.1B
HLNHaleon plc64.5middling$38.7B
ZTSZoetis Inc.61.2middling$28.8B
UTHRUnited Therapeutics Corporation99.8strong$23.2B
VTRSViatris Inc.54.4middling$20.2B
NBIXNeurocrine Biosciences, Inc.98.4strong$14.6B
ELANElanco Animal Health Incorporated84.0good$11.1B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.